10/01/2026
https://www.facebook.com/share/p/19wbHZJ9aS/?mibextid=wwXIfr
Kyverna Therapeutics has shared a letter with the SPS community about its clinical program for miv-cel (KYV-101), an investigational CAR T-cell therapy for stiff person syndrome.
Kyverna has announced positive one-year topline results from KYSA-8, its registrational trial in SPS. These follow the 16-week data Dr. Amanda Piquet presented at the American Academy of Neurology meeting in April. Kyverna says the one-year data will be included in its Biologics License Application to the FDA, which it expects to complete in the fourth quarter of this year. Full results haven't been released yet while the company prepares for FDA review.
We're grateful to Kyverna for keeping the SPS community informed, and to their team for spending time with so many of you at The SPSRF 2026 Symposium in June. Read CEO Warner Biddle's full letter here:
https://www.stiffperson.org/kyverna-update-2025-09-28
://www.stiffperson.org/kyverna-update-2025-09-28